Comparing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP)

Profitability

This table compares Pasithea Therapeutics and MusclePharm’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-81.57%	-74.31%
MusclePharm	-38.51%	N/A	-169.56%

Institutional and Insider Ownership

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 15.5% of MusclePharm shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 60.7% of MusclePharm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Pasithea Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, MusclePharm has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500.

Valuation & Earnings

This table compares Pasithea Therapeutics and MusclePharm”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	$20,000.00	179.14	-$15.96 million	N/A	N/A
MusclePharm	$50.04 million	0.00	-$12.87 million	($0.58)	N/A

MusclePharm has higher revenue and earnings than Pasithea Therapeutics.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

About MusclePharm

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.